Clinical Trials

Thoracic

Small Cell Lung Carcinoma

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06810141 2026-01-14

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms

NCT05619367 2025-12-23

A Compassionate Use (CU) Program of Odronextamab

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04771078 2025-12-12

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Plasma cell

Multiple Myeloma

NCT04400591 2025-12-11

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

Lymphoma, Large B-Cell, Diffuse

NCT05100134 2025-12-09

Managed Access Programs for LDK378, Ceritinib

LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT03601442 2025-12-05

CTL019 Out of Specification MAP for ALL or DLBCL Patients

LymphoidOther hematologic neoplasm

Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04360005 2025-12-05

Managed Access Programs for ABL001, Asciminib

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05038631 2025-12-02

Managed Access Programs for LEE011, Ribociclib

Breast

Breast Neoplasms

NCT05776160 2025-12-01

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Lymphoma, Follicular

NCT04745637 2025-11-18

Managed Access Programs for INC424, Ruxolitinib

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT02632994 2025-09-29

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Neoplasms

NCT06048081 2025-09-10

Early Access Program for Zolbetuximab

Adenocarcinoma

NCT06090331 2025-07-08

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Carcinoma, Renal Cell

NCT06362590 2025-06-17

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT05650476 2025-06-12

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Neoplasm Metastasis, Prostatic Neoplasms

NCT04809233 2025-06-04

Expanded Access to Tipifarnib

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT05738538 2025-06-04

Expanded Access to Ziftomenib

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06980506 2025-05-22

MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Neoplasms

NCT06980519 2025-05-22

MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Neoplasms

NCT05572970 2025-04-30

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Neoplasms

NCT06743100 2025-04-02

18F-Floretyrosine Expanded Access Program

CNS

Glioma

NCT05134922 2025-03-21

Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

Breast

Breast Neoplasm Malignant Female

NCT03775187 2025-03-05

Expanded Access to Burosumab

Oncogenic osteomalacia, Familial Hypophosphatemic Rickets

NCT05494411 2025-02-28

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Carcinoma, Transitional Cell

NCT06149663 2025-01-22

Intermediate-Size Expanded Access Protocol (EAP) for LP352

CDKL5 deficiency disorder, Epilepsy, Epilepsies, Myoclonic, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT05776134 2025-01-10

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

LymphoidOther hematologic neoplasm

Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06751524 2024-12-30

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval